Arcutis Biotherapeutics, Inc. Announces ZORYVE®? (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Published: 2025-06-26 09:35:42 ET ARQT

Published on 06/26/2025 at 09:35

Arcutis Biotherapeutics, Inc. announced that ZORYVE®? (roflumilast) cream 0.15% has received a strong recommendation in the focused guideline update for the management of adult AD from AAD from AAD. The recommendation highlights ZORYVE's ability to deliver clinically meaningful improvements in pruritus and disease severity, its favorable tolerability profile, and low rates of treatment discontinuation, offering adults and pediatric patients 6 years of age and older with mild to moderate AD an effective, non-steroid option for daily disease management.

The AAD's strong recommendation helps guide clinicians and patients toward treatments that deliver clinically meaningful improvements in disease severity while being safe and well tolerated for long-term use. The focused update incorporates newly Food and Drug Administration (FDA)-approved topical and biologic therapies into existing guidelines to ensure that the dermatology community has access to the most current, evidence-based recommendations for managing this chronic condition.